| Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias MW Schmitt, JR Pritchard, SM Leighow, BI Aminov, L Beppu, DS Kim, ... Clinical Cancer Research 24 (21), 5321-5334, 2018 | 39 | 2018 |
| Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts TNA Tran, NB Wikle, E Albert, H Inam, E Strong, K Brinda, SM Leighow, ... BMC medicine 19, 1-14, 2021 | 33 | 2021 |
| Multi-scale predictions of drug resistance epidemiology identify design principles for rational drug design SM Leighow, C Liu, H Inam, B Zhao, JR Pritchard Cell reports 30 (12), 3951-3963. e4, 2020 | 18 | 2020 |
| SARS-CoV-2 epidemic after social and economic reopening in three US states reveals shifts in age structure and clinical characteristics NB Wikle, TNA Tran, B Gentilesco, SM Leighow, E Albert, ER Strong, ... Science advances 8 (4), eabf9868, 2022 | 14 | 2022 |
| Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts TNA Tran, N Wikle, J Albert, H Inam, E Strong, K Brinda, SM Leighow, ... Medrxiv, 2021 | 10 | 2021 |
| Deciphering the mechanistic basis for perfluoroalkyl‐protein interactions A Lawanprasert, JN Sloand, M González Vargas, H Singh, T Eldor, ... ChemBioChem 24 (13), e202300159, 2023 | 6 | 2023 |
| SARS-CoV-2 attack rate and population immunity in Southern New England, March 2020 to May 2021 TNA Tran, NB Wikle, F Yang, H Inam, S Leighow, B Gentilesco, P Chan, ... JAMA network open 5 (5), e2214171-e2214171, 2022 | 6 | 2022 |
| A pan-CRISPR analysis of mammalian cell specificity identifies ultra-compact sgRNA subsets for genome-scale experiments B Zhao, Y Rao, S Leighow, EP O’Brien, L Gilbert, JR Pritchard Nature communications 13 (1), 625, 2022 | 5 | 2022 |
| Agent-based models help interpret patterns of clinical drug resistance by contextualizing competition between distinct drug failure modes SM Leighow, B Landry, MJ Lee, SR Peyton, JR Pritchard Cellular and Molecular Bioengineering 15 (5), 521-533, 2022 | 4 | 2022 |
| Programming tumor evolution with selection gene drives to proactively combat drug resistance SM Leighow, JA Reynolds, I Sokirniy, S Yao, Z Yang, H Inam, D Wodarz, ... Nature Biotechnology, 1-15, 2024 | 3 | 2024 |
| Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing C Liu, SM Leighow, K McIlroy, M Lu, KA Dennis, K Abello, DJ Brown, ... Cell Reports Medicine 4 (10), 2023 | 1 | 2023 |
| The risks of perpetuating an evolutionary arms race in drug discovery SM Leighow, JR Pritchard Evolution, Medicine, and Public Health 2019 (1), 64-65, 2019 | 1 | 2019 |
| Abstract A028: Quantifying resistance to targeted anticancer therapies at scale with duplex sequencing H Inam, J Reynolds, M Tomaszkiewicz, S Leighow, Y Rao, I Sokirniy, ... Cancer Research 84 (3_Supplement_2), A028-A028, 2024 | | 2024 |
| Programmed evolution: Using asexual gene drives to sculpt tumor populations and combat genetic diversity J Pritchard, S Leighow, J Reynolds, I Sokirniy, S Yao, Z Yang, H Inam, ... | | 2023 |
| Pooled and accurate quantification of Variants of Unknown Drug Resistance in the BCR-ABL fusion protein using error-corrected NGS H Inam, J Reynolds, M Tomaszkiewicz, I Sokirniy, S Leighow, Z Yang, ... The dissertation of Haider Inam was reviewed and approved by the following, 23, 2023 | | 2023 |
| Abstract B014: Massively parallel functional assessment of label-free mutant pools is a universal approach to parametrize mechanistic models of drug resistance evolution H Inam, S Leighow, J Pritchard Cancer Research 82 (10_Supplement), B014-B014, 2022 | | 2022 |
| Abstract PR014: Design and construction of evolutionary-guided" selection gene drive" therapy SM Leighow, H Inam, JR Pritchard Cancer Research 82 (10_Supplement), PR014-PR014, 2022 | | 2022 |
| Forecasting and Forward Engineering Anticancer Drug Resistance S Leighow Pennsylvania State University, 2022 | | 2022 |
| Exploiting the “survival of the likeliest” to enable evolution-guided drug design C Liu, SM Leighow, H Inam, B Zhao, JR Pritchard bioRxiv, 557645, 2019 | | 2019 |
